ATE212847T1 - Verwendung von phenol substituierten diphosphonaten als antineoplastische substanten - Google Patents

Verwendung von phenol substituierten diphosphonaten als antineoplastische substanten

Info

Publication number: ATE212847T1
Authority: AT; Austria
Prior art keywords: pct; substants; antineoplastic; phenol substituted; sec
Prior art date: 1995-07-28

Application number

AT96928381T

Other languages

English (en)

Inventor

Eric Niesor

Craig Leigh Bentzen

Lan Mong Nguyen

Jean-Luc Thuillard

Hieu Trung Phan

Jean Flach

Original Assignee

Symphar Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-07-28

Filing date

1996-07-26

Publication date

2002-02-15

1996-07-26 Application filed by Symphar Sa filed Critical Symphar Sa

2002-02-15 Application granted granted Critical

2002-02-15 Publication of ATE212847T1 publication Critical patent/ATE212847T1/de

Links

ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical group OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 title 1
230000000118 anti-neoplastic effect Effects 0.000 title 1
210000004027 cell Anatomy 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000001613 neoplastic effect Effects 0.000 abstract 1
230000009466 transformation Effects 0.000 abstract 1
210000004881 tumor cell Anatomy 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4025—Esters of poly(thio)phosphonic acids
- C07F9/404—Esters of poly(thio)phosphonic acids containing hydroxy substituents in the hydrocarbon radicals

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Compounds Of Unknown Constitution (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT96928381T 1995-07-28 1996-07-26 Verwendung von phenol substituierten diphosphonaten als antineoplastische substanten ATE212847T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CH02213/95A CH690163A5 (fr)	1995-07-28	1995-07-28	Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers.
PCT/EP1996/003301 WO1997004785A1 (en)	1995-07-28	1996-07-26	Use of phenol substituted diphosphonates as antineoplastic agents

Publications (1)

Publication Number	Publication Date
ATE212847T1 true ATE212847T1 (de)	2002-02-15

Family

ID=4228513

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT96928381T ATE212847T1 (de)	1995-07-28	1996-07-26	Verwendung von phenol substituierten diphosphonaten als antineoplastische substanten

Country Status (14)

Country	Link
US (1)	US6127350A (de)
EP (1)	EP0845991B1 (de)
JP (1)	JPH11511127A (de)
CN (1)	CN1091601C (de)
AT (1)	ATE212847T1 (de)
AU (1)	AU723094B2 (de)
CA (1)	CA2228212A1 (de)
CH (1)	CH690163A5 (de)
DE (1)	DE69619117T2 (de)
DK (1)	DK0845991T3 (de)
ES (1)	ES2172675T3 (de)
PT (1)	PT845991E (de)
WO (1)	WO1997004785A1 (de)
ZA (1)	ZA966364B (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9603637D0 (en) *	1996-02-21	1996-04-17	Smithkline Beecham Plc	Process
US6555529B1 (en)	1997-12-25	2003-04-29	Toray Industries, Inc.	Remedies for intramedullary diseases
AU785355B2 (en) *	1999-12-03	2007-02-01	Regents Of The University Of California At San Diego, The	Phosphonate compounds
GB0019272D0 (en) *	2000-08-04	2000-09-27	Symphar Sa	Pharmaceutical compounds
CA2451881A1 (fr)	2001-07-16	2003-01-30	Universite Paris 13	Nouveaux derives de bisphosphonates, leurs preparations et utilisations
FR2827289B1 (fr) *	2001-07-16	2004-07-23	Univ Paris 13	Nouveau derive d'acide diphosphonique, son application en therapeutique et procede de preparation
EP1435970A4 (de) *	2001-10-18	2005-05-04	Ilex Products Inc	Verfahren zur behandlung der haut mit diphosphonat-derivaten
US20060205692A1 (en) *	2002-05-11	2006-09-14	Montes Imber F	1,1-and 1,2-Bisphosphonates as apoliprotein e modulators
JP2006503023A (ja) *	2002-09-03	2006-01-26	バイオヴェイルラボラトリーズインコーポレイテッド	スタチン薬物の放出調節ための医薬品製剤および方法
AU2003272534A1 (en) *	2002-09-19	2004-04-08	Ilex Oncology Research, Sarl	Therapeutic uses of linear ketophosphonates
US8362075B2 (en)	2005-05-17	2013-01-29	Merck Sharp & Dohme Corp.	Cyclohexyl sulphones for treatment of cancer
TW200804345A (en)	2005-08-30	2008-01-16	Novartis Ag	Substituted benzimidazoles and methods of preparation
GB0603041D0 (en)	2006-02-15	2006-03-29	Angeletti P Ist Richerche Bio	Therapeutic compounds
DK2010528T3 (en)	2006-04-19	2018-01-15	Novartis Ag	6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods for Inhibiting CSF-1R Signaling
US8173629B2 (en)	2006-09-22	2012-05-08	Merck Sharp & Dohme Corp.	Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en)	2006-11-01	2011-09-08	Barbara Brooke Jennings-Spring	Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EA016079B1 (ru)	2007-01-10	2012-01-30	Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа	Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp)
ES2431163T3 (es)	2007-03-01	2013-11-25	Novartis Ag	Inhibidores de PIM quinasa y métodos para su uso
BRPI0812159A2 (pt)	2007-05-21	2017-05-02	Novartis Ag	inibidores de csf-1r, composições e métodos de uso
AU2008269154B2 (en)	2007-06-27	2014-06-12	Merck Sharp & Dohme Llc	4-carboxybenzylamino derivatives as histone deacetylase inhibitors
WO2010114780A1 (en)	2009-04-01	2010-10-07	Merck Sharp & Dohme Corp.	Inhibitors of akt activity
EP2440058A4 (de)	2009-06-12	2012-11-21	Dana Farber Cancer Inst Inc	Verschmolzene heterozyklische verbindungen und anwendungen davon
JP5099731B1 (ja)	2009-10-14	2012-12-19	メルク・シャープ・アンド・ドーム・コーポレーション	ｐ５３活性を増大する置換ピペリジン及びその使用
EP2937345B1 (de)	2009-12-29	2018-03-21	Dana-Farber Cancer Institute, Inc.	Typ-ii-raf-kinase-hemmer
BR112012023021A2 (pt)	2010-03-16	2016-05-31	Dana Farber Cancer Inst Inc	compostos de indazol e seus usos
EP2584903B1 (de)	2010-06-24	2018-10-24	Merck Sharp & Dohme Corp.	Neue heterozyklische verbindungen als erk-hemmer
AU2011285909B2 (en)	2010-08-02	2016-11-10	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP2606134B1 (de)	2010-08-17	2019-04-10	Sirna Therapeutics, Inc.	Rna-interferenz-vermittelte hemmung der hepatitis b-virus (hbv)-genexpression mittels kurzer interferierender nukleinsäure (sina)
US8883801B2 (en)	2010-08-23	2014-11-11	Merck Sharp & Dohme Corp.	Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (de)	2010-09-01	2016-11-02	Merck Sharp & Dohme Corp.	Indazolderivate als erk-hemmer
US9242981B2 (en)	2010-09-16	2016-01-26	Merck Sharp & Dohme Corp.	Fused pyrazole derivatives as novel ERK inhibitors
EP3766975A1 (de)	2010-10-29	2021-01-20	Sirna Therapeutics, Inc.	Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina)
EP2654748B1 (de)	2010-12-21	2016-07-27	Merck Sharp & Dohme Corp.	Indazolderivate als erk-hemmer
EP2699567A1 (de)	2011-04-21	2014-02-26	Merck Sharp & Dohme Corp.	Hemmer des insulinähnlichen wachstumsfaktor-1-rezeptors
WO2013063214A1 (en)	2011-10-27	2013-05-02	Merck Sharp & Dohme Corp.	Novel compounds that are erk inhibitors
WO2013074986A1 (en)	2011-11-17	2013-05-23	Dana-Farber Cancer Institute, Inc.	Inhibitors of c-jun-n-terminal kinase (jnk)
KR102317166B1 (ko)	2012-03-23	2021-10-26	어레이 바이오파마 인크.	뇌암의 치료
EP3358013B1 (de)	2012-05-02	2020-06-24	Sirna Therapeutics, Inc.	Sina-zusammensetzungen
KR20150060724A (ko)	2012-09-28	2015-06-03	머크 샤프 앤드 돔 코포레이션	Erk 억제제인 신규 화합물
US10112927B2 (en)	2012-10-18	2018-10-30	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10000483B2 (en)	2012-10-19	2018-06-19	Dana-Farber Cancer Institute, Inc.	Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US9758522B2 (en)	2012-10-19	2017-09-12	Dana-Farber Cancer Institute, Inc.	Hydrophobically tagged small molecules as inducers of protein degradation
DK2925888T3 (en)	2012-11-28	2017-12-18	Merck Sharp & Dohme	COMPOSITIONS AND METHODS OF CANCER TREATMENT
EP2935263B1 (de)	2012-12-20	2018-12-05	Merck Sharp & Dohme Corp.	Substituierte imidazopyridine als hdm2 inhibitoren
US9540377B2 (en)	2013-01-30	2017-01-10	Merck Sharp & Dohme Corp.	2,6,7,8 substituted purines as HDM2 inhibitors
WO2015034925A1 (en)	2013-09-03	2015-03-12	Moderna Therapeutics, Inc.	Circular polynucleotides
WO2015058126A1 (en)	2013-10-18	2015-04-23	Syros Pharmaceuticals, Inc.	Heteroaromatic compounds useful for the treatment of prolferative diseases
WO2015058140A1 (en)	2013-10-18	2015-04-23	Dana-Farber Cancer Institute, Inc.	Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2015164604A1 (en)	2014-04-23	2015-10-29	Dana-Farber Cancer Institute, Inc.	Hydrophobically tagged janus kinase inhibitors and uses thereof
US10017477B2 (en)	2014-04-23	2018-07-10	Dana-Farber Cancer Institute, Inc.	Janus kinase inhibitors and uses thereof
JO3589B1 (ar)	2014-08-06	2020-07-05	Novartis Ag	مثبطات كيناز البروتين c وطرق استخداماتها
EP3209671B8 (de) *	2014-10-21	2019-07-31	Council of Scientific and Industrial Research	Alkyliden-phosphonat-ester als p-glycoproteininduktoren
AU2015371251B2 (en)	2014-12-23	2020-06-11	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN107427521B (zh)	2015-03-27	2021-08-03	达纳-法伯癌症研究所股份有限公司	细胞周期蛋白依赖性激酶的抑制剂
EP3307728A4 (de)	2015-06-12	2019-07-17	Dana Farber Cancer Institute, Inc.	Kombinationstherapie von transkriptionshemmern und kinasehemmern
JP7028766B2 (ja)	2015-09-09	2022-03-02	ダナ－ファーバーキャンサーインスティテュート，インコーポレイテッド	サイクリン依存性キナーゼの阻害剤
CN106986789B (zh) *	2016-01-20	2019-07-16	中国人民解放军军事医学科学院生物医学分析中心	对苯二酚类化合物及其制备方法与在抗肿瘤或免疫调节中的应用
JOP20190055A1 (ar)	2016-09-26	2019-03-24	Merck Sharp & Dohme	أجسام مضادة ضد cd27
WO2018071283A1 (en)	2016-10-12	2018-04-19	Merck Sharp & Dohme Corp.	Kdm5 inhibitors
WO2018190719A2 (en)	2017-04-13	2018-10-18	Aduro Biotech Holdings, Europe B.V.	Anti-sirp alpha antibodies
US11098059B2 (en)	2017-11-08	2021-08-24	Merck Sharp & Dohme Corp.	PRMT5 inhibitors
WO2019094311A1 (en)	2017-11-08	2019-05-16	Merck Sharp & Dohme Corp.	Prmt5 inhibitors
WO2019148412A1 (en)	2018-02-01	2019-08-08	Merck Sharp & Dohme Corp.	Anti-pd-1/lag3 bispecific antibodies
JP7590185B2 (ja)	2018-06-25	2024-11-26	ダナ－ファーバーキャンサーインスティテュート，インコーポレイテッド	Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
EP3833667B1 (de)	2018-08-07	2024-03-13	Merck Sharp & Dohme LLC	Prmt5-inhibitoren
EP3833668B1 (de)	2018-08-07	2025-03-19	Merck Sharp & Dohme LLC	Prmt5-inhibitoren
BR112021002267A8 (pt)	2018-08-07	2023-02-07	Merck Sharp & Dohme	Inibidores de prmt5
WO2020033285A1 (en)	2018-08-07	2020-02-13	Merck Sharp & Dohme Corp.	Prmt5 inhibitors
WO2020140098A1 (en)	2018-12-28	2020-07-02	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 and uses thereof
EP4076460B1 (de)	2019-12-17	2026-01-21	Merck Sharp & Dohme LLC	1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidin]-derivate als prmt5 inhibitoren zur behandlung von krebs
BR112022012015A2 (pt)	2019-12-17	2022-08-30	Merck Sharp & Dohme Llc	Inibidores de prmt5
CA3160153A1 (en)	2019-12-17	2021-06-24	Michelle Machacek	Prmt5 inhibitors
JP2026509792A (ja)	2023-03-02	2026-03-25	カルツィムンビオテックゲゼルシャフトミットベシュレンクテルハフツング	がん及び／又は急性炎症性疾患を診断するための手段及び方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH675422A5 (de) *	1988-03-31	1990-09-28	Symphar Sa
JPH0377894A (ja) *	1989-08-18	1991-04-03	Toray Ind Inc	メチレンジホスホン酸化合物

1995
- 1995-07-28 CH CH02213/95A patent/CH690163A5/fr not_active IP Right Cessation
1996
- 1996-07-26 CA CA002228212A patent/CA2228212A1/en not_active Abandoned
- 1996-07-26 JP JP9507232A patent/JPH11511127A/ja active Pending
- 1996-07-26 AU AU67874/96A patent/AU723094B2/en not_active Ceased
- 1996-07-26 DE DE69619117T patent/DE69619117T2/de not_active Expired - Fee Related
- 1996-07-26 CN CN96196005A patent/CN1091601C/zh not_active Expired - Fee Related
- 1996-07-26 WO PCT/EP1996/003301 patent/WO1997004785A1/en not_active Ceased
- 1996-07-26 DK DK96928381T patent/DK0845991T3/da active
- 1996-07-26 ZA ZA966364A patent/ZA966364B/xx unknown
- 1996-07-26 EP EP96928381A patent/EP0845991B1/de not_active Expired - Lifetime
- 1996-07-26 ES ES96928381T patent/ES2172675T3/es not_active Expired - Lifetime
- 1996-07-26 US US09/011,247 patent/US6127350A/en not_active Expired - Fee Related
- 1996-07-26 AT AT96928381T patent/ATE212847T1/de not_active IP Right Cessation
- 1996-07-26 PT PT96928381T patent/PT845991E/pt unknown

Also Published As

Publication number	Publication date
DK0845991T3 (da)	2002-05-27
CH690163A5 (fr)	2000-05-31
AU6787496A (en)	1997-02-26
US6127350A (en)	2000-10-03
JPH11511127A (ja)	1999-09-28
CN1192148A (zh)	1998-09-02
CN1091601C (zh)	2002-10-02
WO1997004785A1 (en)	1997-02-13
DE69619117T2 (de)	2002-09-19
AU723094B2 (en)	2000-08-17
ES2172675T3 (es)	2002-10-01
EP0845991B1 (de)	2002-02-06
HK1015686A1 (en)	1999-10-22
DE69619117D1 (de)	2002-03-21
CA2228212A1 (en)	1997-02-13
EP0845991A2 (de)	1998-06-10
PT845991E (pt)	2002-07-31
ZA966364B (en)	1997-02-11

Legal Events

Date	Code	Title	Description
2002-06-15	UEP	Publication of translation of european patent specification
2007-04-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69619117D1 (de)	2002-03-21	Verwendung von phenol substituierten diphosphonaten als antineoplastische substanten
DE69105495D1 (en)	1995-01-12	Benzylphosphonsäure-tyrosinkinaseinhibitoren.
PT841929E (pt)	2003-09-30	Quinolonas e sua utilizacao terapeutica
TR200800474T2 (tr)	2008-04-21	Florfenikole aracı maddelerin hazırlanmasına ilişkin işlem.
BR9814361A (pt)	2001-11-27	Inibição de quinase raf usando uréiasheterocìclicas substituìdas por arila eheteroarila
DE59903921D1 (de)	2003-02-06	Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
DE69633679D1 (de)	2004-11-25	Substituierte aryl-oder heteroarylamide mit retinoid-ähnlicher biologischer aktivität
BR9609888A (pt)	1999-05-25	Halogenobenzimidazóis
ATE226201T1 (de)	2002-11-15	Substituierte pyridylpyrazole
FI934223A0 (fi)	1993-09-27	Heterocykliscykliska aminderivat
BR9909844A (pt)	2001-04-03	Processo para sintetizar um composto, e, composto.
PL333429A1 (en)	1999-12-06	Benzonaphtyridines useful in particular in treating bronchial diseases
AU5648496A (en)	1996-11-29	Pyrazolo-(1,5a)pyrimidines, their preparation and their use
FI973221A0 (fi)	1997-08-04	1-aryyli-2-asyyliammo-etaaniyhdisteitä ja niiden käyttö neurokiniiniantagonisteina, erityisesti neurokiniini 1 antagonisteina
DE69510545D1 (de)	1999-08-05	Cck oder gastrin modulierende 5-heterocyclicyl-1,5-benzodiazepine
TR199901386T2 (en)	1999-09-21	�midazopiridazinler.
DE69703796D1 (de)	2001-02-01	N-bis- oder n-tris-[(1,2-dicarboxy-ethoxy)-ethyl]-amin-derivate und herstellung und anwendung derselben
TR199701202T1 (xx)	1998-03-21	Yeni hidroksimik asit t�revleri.
ATE215084T1 (de)	2002-04-15	Imidazopyridin-azolidinone
IT1293777B1 (it)	1999-03-10	Processo per la preparazione di tetraazamacrocicli
DE59709920D1 (de)	2003-05-28	N-sulfonylimidazole als fungizide
MX9801133A (es)	1998-05-31	Agente endoparasiticida a base de didepsipeptidos, nuevos didepsipeptidos y procedimiento para su produccion.
BR9807785A (pt)	2000-02-22	Processo para a preparação do composto, e, composto
SE9602416D0 (sv)	1996-06-18	New forms of an organic salt of N'N-diacetylcystine
ATE161682T1 (de)	1998-01-15	Zusammensetzung zur behandlung von pflanzenmaterial